Compare Wegovy vs Mounjaro: Expert Prescription Guidance
Online Prescription Process: Wegovy Compared to Mounjaro Assessment
When seeking an online prescription for either Wegovy compared to Mounjaro, the assessment process remains consistent but requires different clinical considerations. Our 3-minute online clinical assessment evaluates your BMI, medical history, current medications, and weight-related health conditions to determine suitability for either treatment. Licensed UK prescribers review each case individually, considering factors like your previous experience with weight management medications and any contraindications specific to GLP-1 agonists or dual GIP/GLP-1 agonists.
The beauty of our online prescription service is that you don't need to choose between Wegovy compared to Mounjaro before your assessment. Our prescribers will recommend the most appropriate option based on your individual circumstances, medical history, and treatment goals. Standard prescription approval takes 3 working days, with express 24-hour service available for urgent cases, ensuring you can start your chosen treatment without lengthy delays.
Pricing Transparency: Wegovy Compared to Mounjaro Costs
Understanding the cost implications when weighing Wegovy compared to Mounjaro is crucial for long-term treatment planning. Wegovy starts at £79.99 for the 0.25mg starter dose (using code FIRST40 for new customers), progressing through £94.99 for 0.5mg, £99.99 for 1mg, £139.99 for 1.7mg, and £209.99 for the 2.4mg maintenance dose. Our Intro Duo bundle (0.25mg & 0.5mg) provides convenient two-month starter supply for £169.99, whilst the Ultimate Stability Trio offers three months of 2.4mg maintenance for £649.99.
Mounjaro pricing follows a different structure due to its distinct dosing schedule, with all costs transparently displayed during your clinical assessment. Both treatments qualify for our discount codes - FIRST40 for new customers and DOSE25 for returning customers - applied automatically at checkout. The financial investment extends beyond initial costs, as both medications require ongoing prescription-only medicine supply with regular clinical reviews to ensure continued safety and efficacy.
Clinical Evidence: Wegovy Compared to Mounjaro Trial Data
Clinical evidence for Wegovy compared to Mounjaro comes from separate trial programmes with different designs and patient populations. The STEP trial programme demonstrated that patients taking Wegovy alongside diet and exercise achieved approximately 15% average weight loss at 68 weeks in STEP 1, whilst STEP 5 showed sustained clinically studied weight loss at 2 years (Wilding et al., NEJM, 2021). The recent SELECT cardiovascular outcomes trial showed a 20% reduction in major cardiovascular events.
Mounjaro's clinical evidence stems from the SURMOUNT trial series, utilising tirzepatide's dual GIP/GLP-1 receptor agonist mechanism. Direct comparison of trial weight loss percentages between these treatments isn't appropriate due to different study designs, patient populations, and endpoints. Both Wegovy and Mounjaro are available from EverydayMeds, where your prescriber can help determine which clinical profile aligns best with your individual circumstances.
How Wegovy Works: Understanding the GLP-1 Mechanism
Wegovy contains semaglutide, a GLP-1 receptor agonist that mimics a natural hormone called glucagon-like peptide-1, which your body produces in response to eating. This prescription-only medicine works by binding to GLP-1 receptors in your brain, specifically in areas that control appetite and food intake, helping to reduce hunger signals and promote feelings of fullness after smaller meals. The medication may also slow gastric emptying, meaning food stays in your stomach longer, contributing to prolonged satiety between meals. Additionally, Wegovy can help reduce food cravings and the psychological drive to eat, particularly for high-calorie, palatable foods. This comprehensive approach to appetite regulation, when used alongside a reduced-calorie diet and increased physical activity, supports sustainable weight management over the long term.
Streamlined Ordering Process for Both Treatments
Our online prescription process for Wegovy compared to Mounjaro eliminates traditional barriers to accessing weight management treatments. The 3-minute clinical assessment covers essential medical history, current BMI calculations, existing medications, and any previous experience with weight management therapies. Once submitted, our licensed prescribers review your application within 3 working days (or 24 hours with express service), considering which treatment option best suits your individual profile. Upon approval, your chosen medication is dispatched via next-day delivery using cold-chain, temperature-controlled packaging to maintain medication integrity. All orders include comprehensive patient information leaflets, injection technique guidance, and access to our clinical support team throughout your treatment journey.
Storage and Practical Considerations: Key Differences
Storage requirements represent a practical difference when considering Wegovy compared to Mounjaro for your lifestyle needs. Wegovy offers superior travel convenience, remaining stable at room temperature (below 30°C) for up to 6 weeks once removed from refrigeration, compared to Mounjaro's 21-day room temperature limit. Both medications require initial refrigeration at 2-8°C before first use and utilise pre-filled pen devices for once-weekly subcutaneous injection. The FlexTouch pen system for Wegovy provides dose escalation from 0.25mg through to 2.4mg maintenance, with clear dose windows and audible click confirmation. Proper injection technique training is provided with your first prescription, ensuring confident self-administration throughout your treatment course.
Dual vs Single Mechanism: Wegovy Compared to Mounjaro Science
The fundamental difference when examining Wegovy compared to Mounjaro lies in their receptor targeting mechanisms. Wegovy works exclusively through GLP-1 receptor agonism, providing proven appetite suppression and weight management benefits through this single pathway. Mounjaro utilises tirzepatide, a dual GIP/GLP-1 receptor agonist that targets both glucose-dependent insulinotropic polypeptide and GLP-1 receptors simultaneously.
This mechanistic distinction influences prescriber choice when evaluating individual patient profiles through our online prescription service. Some patients may benefit from the established GLP-1-only approach of Wegovy, whilst others might be considered more suitable for dual agonist therapy with Mounjaro. Our clinical assessment captures relevant factors including diabetes status, cardiovascular risk, and previous treatment responses to guide this important therapeutic decision.
Start Your Prescription Journey Today
Taking the first step towards professional weight management through our online prescription service removes uncertainty from choosing between Wegovy compared to Mounjaro. Simply complete our 3-minute clinical assessment, where our licensed prescribers will evaluate your suitability for either treatment based on current medical guidelines and your individual circumstances. Use code FIRST40 as a new customer or DOSE25 for returning patients, with transparent pricing displayed throughout the checkout process. Your chosen prescription-only medicine will be dispensed through our GPhC-registered UK pharmacy and delivered via next-day, temperature-controlled shipping. Visit https://everydaymeds.co.uk/collections/wegovy to begin your clinical assessment and take control of your weight management journey with professional medical support.
Reviewed by the EverydayMeds Clinical Team · GPhC #9012878 · Last updated February 2026
